Stock Scorecard



Stock Summary for Laboratory Corp Of America Holdings (LH) - $269.81 as of 1/30/2026 6:35:04 PM EST

Total Score

11 out of 30

Safety Score

48 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LH

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LH

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LH

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LH

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LH (48 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 1
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for LH

GRAIL Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Blood Test 1/30/2026 10:01:00 PM
What Does The Institutional Ownership Tell Us About Fulgent Genetics? 1/30/2026 11:01:00 AM
Labcorp Extends Receivables Facility, Enhances Liquidity Flexibility 1/29/2026 10:09:00 PM
Bank of New York Mellon Corp Sells 23,382 Shares of Labcorp Holdings Inc. $LH 1/29/2026 10:09:00 AM
Parp Inhibitor Biomarkers Market Generated Opportunities, Future Scope 2026-2033 |Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation 1/28/2026 11:00:00 AM
Lead Competitors in Cold Chain Packaging: Pelican BioThermal, Intelsius, Cryopak, Sonoco ThermoSafe, and Va-Q-tec 1/26/2026 4:58:00 PM
Waters Corporation: How a Quiet Lab Workhorse Became a Strategic Tech Platform 1/26/2026 1:16:00 PM
Comparator Drug Sourcing Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Clinigen, BAP Pharma Group, Thermo Fisher Scientific, Laboratory Corporation of America, Catalent and More 1/26/2026 12:20:00 PM
Sector Gamma AS Acquires 6,486 Shares of Labcorp Holdings Inc. $LH 1/25/2026 12:35:00 PM
Strs Ohio Reduces Stake in Labcorp Holdings Inc. $LH 1/25/2026 10:48:00 AM

Financial Details for LH

Company Overview

Ticker LH
Company Name Laboratory Corp Of America Holdings
Country N/A
Description Laboratory Corporation of America Holdings (Labcorp), headquartered in Burlington, North Carolina, stands as a leading global life sciences organization focused on enhancing patient care through its comprehensive laboratory services and solutions. With an extensive network of 36 clinical laboratories across the United States, Labcorp delivers a wide array of diagnostic testing and drug development services, facilitating innovations in healthcare. Leveraging cutting-edge technology and data analytics, the company is at the forefront of personalized medicine, playing a pivotal role in advancing public health and therapeutic strategies worldwide.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 9/30/2025
Next Earnings Date 2/17/2026

Stock Price History

Last Day Price 269.81
Price 4 Years Ago 194.90
Last Day Price Updated 1/30/2026 6:35:04 PM EST
Last Day Volume 749,921
Average Daily Volume 744,539
52-Week High 292.94
52-Week Low 207.67
Last Price to 52 Week Low 29.92%

Valuation Measures

Trailing PE N/A
Industry PE 42.12
Sector PE 95.54
5-Year Average PE 14.04
Free Cash Flow Ratio 37.42
Industry Free Cash Flow Ratio 55.27
Sector Free Cash Flow Ratio 26.23
Current Ratio Most Recent Quarter 1.55
Total Cash Per Share 7.21
Book Value Per Share Most Recent Quarter 104.78
Price to Book Ratio 2.58
Industry Price to Book Ratio 10.13
Sector Price to Book Ratio 22.01
Price to Sales Ratio Twelve Trailing Months 1.64
Industry Price to Sales Ratio Twelve Trailing Months 4.86
Sector Price to Sales Ratio Twelve Trailing Months 18.97
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 82,900,000
Market Capitalization 22,367,249,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date 2/27/2026
Previous Dividend Amount 0.7200
Current Dividend Amount 0.7200
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 2.88
Trailing Annual Dividend Yield 1.07%
Forward Annual Dividend Rate 2.88
Forward Annual Dividend Yield 1.07%
5-Year Dividend Payments Count 16
3-Year Average Dividend Yield 1.15%
5-Year Average Dividend Yield 1.24%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 37.74%
All-Time Dividend Growth Rate Percentage 31.95%
Dividend Payout Ratio 28.29%

Income Statement

Quarterly Earnings Growth YOY 56.00%
Annual Earnings Growth 78.47%
Reported EPS 12 Trailing Months 10.18
Reported EPS Past Year 12.37
Reported EPS Prior Year 14.57
Net Income Twelve Trailing Months 855,200,000
Net Income Past Year 746,000,000
Net Income Prior Year 418,000,000
Quarterly Revenue Growth YOY 8.60%
5-Year Revenue Growth 2.40%
Operating Margin Twelve Trailing Months 11.30%

Balance Sheet

Total Cash Most Recent Quarter 598,100,000
Total Cash Past Year 1,518,700,000
Total Cash Prior Year 536,800,000
Net Cash Position Most Recent Quarter -4,484,400,000
Net Cash Position Past Year -3,812,500,000
Long Term Debt Past Year 5,331,200,000
Long Term Debt Prior Year 4,054,700,000
Total Debt Most Recent Quarter 5,082,500,000
Equity to Debt Ratio Past Year 0.60
Equity to Debt Ratio Most Recent Quarter 0.63
Total Stockholder Equity Past Year 8,052,200,000
Total Stockholder Equity Prior Year 7,875,000,000
Total Stockholder Equity Most Recent Quarter 8,696,900,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 1,380,800,000
Free Cash Flow Per Share Twelve Trailing Months 16.66
Free Cash Flow Past Year 1,095,900,000
Free Cash Flow Prior Year 874,100,000

Options

Put/Call Ratio 0.15
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.85
MACD Signal 1.81
20-Day Bollinger Lower Band 244.58
20-Day Bollinger Middle Band 265.91
20-Day Bollinger Upper Band 287.24
Beta 0.97
RSI 56.85
50-Day SMA 255.80
150-Day SMA 224.67
200-Day SMA 217.97

System

Modified 1/29/2026 2:36:11 AM EST